Alemtuzumab as Treatment for Multiple Sclerosis

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Immunotherapy

Background:

• Alemtuzumab, a humanized monoclonal antibody, has been used in multiple sclerosis (MS) treatment since 1991.
• Its efficacy was established in hematology, oncology, and transplantation before its use in MS.

Purpose of the Study:

• To evaluate the efficacy and safety of alemtuzumab in treating multiple sclerosis.
• To assess long-term outcomes and side effects of alemtuzumab therapy.

Main Methods:

• Phase 2 and 3 clinical trials comparing alemtuzumab to interferon β-1a.
• Longer-term extension studies to track durable effects and relapse rates.
• Monitoring for adverse events, particularly secondary autoimmunity.

Main Results:

• Alemtuzumab demonstrated superior short-term efficacy over interferon β-1a in reducing relapse rates and disability accumulation.
• Longer-term studies showed sustained slowing of cerebral atrophy and low relapse rates, even with reduced dosing.
• The most common side effects include secondary autoimmunity affecting the thyroid, platelets, and kidneys, occurring 1-2 years post-infusion.

Conclusions:

• Alemtuzumab offers durable, high efficacy for multiple sclerosis with infrequent dosing.
• Patient and physician adherence to safety monitoring is crucial due to the risk of secondary autoimmunity.
• Alemtuzumab represents a significant therapeutic advance for managing MS, balancing efficacy with manageable risks.